GlassScriptPhysician profile
Phillip G Davis
NPI 1508852476
$2,610.70
in general payments reported to CMS, 2019-2025
29 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $357 · 2021: $414 · 2022: $323 · 2023: $485 · 2024: $485 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $458.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $340.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $311.30 | 2019-2025 | |
| Lilly USA, LLC | $271.78 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $251.49 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $122.13 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $103.09 | 2020-2024 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $103.05 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.95 | 2020-2025 | Jardiance |
| Esperion Therapeutics, INC. | $69.37 | 2024 | Nexletol |
| Abbvie INC. | $63.81 | 2021-2022 | |
| Exact Sciences Corporation | $62.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $54.77 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $53.80 | 2021-2023 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $33.78 | 2022-2023 | Gralise, Sertraline Hcl, Loreev Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.40 | 2020-2021 | |
| Astellas Pharma US INC | $22.85 | 2025 | Veozah |
| Vivus LLC | $20.46 | 2024 | Qsymia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.68 | 2024 | Xifaxan |
| Genzyme Corporation | $17.31 | 2023 | |
| Insmed, INC. | $16.92 | 2025 | Arikayce |
| Amarin Pharma, INC. | $16.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.51 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $15.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.87 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $13.85 | 2023 | Krystexxa |
| Metuchen Pharmaceuticals | $12.95 | 2019 | |
| Philips North America LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.